Abstract:Background: Azithromycin (AZM) is widely being used for treating patients with cystic fibrosis (pwCF) following clinical trials demonstrating improved lung function and fewer incidents of pulmonary exacerba-tions. While the precise mechanisms remain elusive, immunomodulatory actions are thought to be involved. We previously reported impaired phagocytosis and defective anti-inflammatory M2 macrophage polarization in CF. This study systematically analyzed the effect of AZM on the functions of unpolarized and M1/M2 polarized macrophages in CF. Methods: Monocytes, isolated from the venous blood of patients with CF (pwCF) and healthy controls (HCs), were differentiated into monocyte-derived macrophages (MDMs) and subsequently infected with P. aeruginosa. P. aeruginosa uptake and killing by MDMs in the presence or absence of AZM was studied. M1 and M2 macrophage polarizations were induced and their functions and cytokine release were analyzed. Results: Following AZM treatment, both HC and CF MDMs exhibited a significant increase in P. aeruginosa uptake and killing, however, lysosomal acidification remained unchanged. AZM treatment led to higher activation of ERK1/2 in both HC and CF MDMs. Pharmacological inhibition of ERK1/2 using U0126 significantly reduced P. aeruginosa uptake in HC MDMs. M1 macrophage polarization remained unaffected; however, AZM treatment led to increased IL-6 and IL-10 release in both HC and CF M1 macrophages. AZM also significantly increased the phagocytic index for both pHrodo E. coli and S. aureus in CF M1 macrophages. In CF, AZM treatment promoted anti-inflammatory M2 macrophage polarization, with an increased percentage of CD209+ M2 macrophages, induction of the M2 gene CCL18, along with its secretion in the culture supernatant. However, AZM d'd not restore endocytosis in CF, another essential feature of M2 macrophages. Conclusions: This study highlights the cellular functions and molecular targets of AZM which may involve an improved uptake of both Gram-positive and Gram-negative bacteria, restored anti-inflammatory macrophage polarization in CF. This may in turn shape the reduced lung inflammation observed in clinical trials. In addition, we confirmed the role of ERK1/2 activation for bacterial uptake.

Azithromycin Polarizes Macrophages to an M2 Phenotype via Inhibition of the STAT1 and NF-κB Signaling Pathways

Azithromycin alters macrophage phenotype

Azithromycin Augments Bacterial Uptake and Anti-Inflammatory Macrophage Polarization in Cystic Fibrosis

Azithromycin targets the CD27 pathway to modulate CD27hi T-lymphocyte expansion and type-1 effector phenotype

Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity

Macrolide derivatives reduce proinflammatory macrophage activation and macrophage-mediated neurotoxicity

Azithromycin Promotes Alternatively Activated Macrophage Phenotype in Systematic Lupus Erythematosus Via PI3K/Akt Signaling Pathway

Inactivation of MST1/2 Controls Macrophage Polarization to Affect Macrophage-Related Disease via YAP and Non-YAP Mechanisms

Azithromycin Alleviates Systemic Lupus Erythematosus Via the Promotion of M2 Polarisation in Lupus Mice.

Macrolide Antibiotics Activate the Integrated Stress Response and Promote Tumor Proliferation.

Azithromycin Suppresses TGF-β1-related Epithelial-Mesenchymal Transition in Airway Epithelial Cells Via Targeting RACK1.

Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice

Cellular zinc homeostasis modulates polarization of THP-1-derived macrophages

Late-breaking Abstract: Azithromycin Plays an Important Role in Treating Diffuse Panbronchiolitis by Specific Inhibition of CXCL-2/MIP-2 and IL-17A in T Cells

Lipopolysaccharide Mediates Time-Dependent Macrophage M1/M2 Polarization Through the Tim-3/Galectin-9 Signalling Pathway

Azithromycin Exerts Bactericidal Activity and Enhances Innate Immune Mediated Killing of MDR Achromobacter xylosoxidans

Isomeranzin Suppresses Inflammation by Inhibiting M1 Macrophage Polarization Through the NF-κB and ERK Pathway.

MiR-19a-3p Suppresses M1 Macrophage Polarization by Inhibiting STAT1/IRF1 Pathway

Azithromycin attenuates myofibroblast differentiation and lung fibrosis development through proteasomal degradation of NOX4

Mycobacterium Tuberculosis Mce2D Protein Blocks M1 Polarization in Macrophages by Inhibiting the ERK Signaling Pathway.

Azithromycin Treats Diffuse Panbronchiolitis by Targeting T Cells Via Inhibition of Mtor Pathway.